Moreno Evelyn V lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,553 shares of the company’s stock after selling 1,515 shares during the quarter. Johnson & Johnson comprises approximately 2.3% of Moreno Evelyn V’s portfolio, making the stock its 13th biggest holding. Moreno Evelyn V’s holdings in Johnson & Johnson were worth $7,613,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of JNJ. State Street Corp boosted its position in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Korea Investment CORP boosted its position in Johnson & Johnson by 38.9% during the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after purchasing an additional 596,134 shares during the period. Bank of Nova Scotia boosted its position in Johnson & Johnson by 94.5% during the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Johnson & Johnson during the first quarter worth about $65,598,000. Finally, CIBC World Markets Inc. boosted its position in Johnson & Johnson by 111.8% during the first quarter. CIBC World Markets Inc. now owns 948,655 shares of the company’s stock worth $118,155,000 after purchasing an additional 500,662 shares during the period. Hedge funds and other institutional investors own 65.90% of the company’s stock.

In other news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.

WARNING: “Moreno Evelyn V Cuts Holdings in Johnson & Johnson (JNJ)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/moreno-evelyn-v-cuts-holdings-in-johnson-johnson-jnj/1585475.html.

A number of equities analysts have recently commented on JNJ shares. J P Morgan Chase & Co raised their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the company an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Tuesday, August 15th. Wells Fargo & Company restated a “market perform” rating and issued a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. BidaskClub lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Cowen and Company set a $147.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, August 24th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $135.29.

Johnson & Johnson (JNJ) traded down 0.27% on Friday, hitting $131.39. 4,334,862 shares of the company’s stock traded hands. The stock has a market cap of $352.65 billion, a P/E ratio of 22.23 and a beta of 0.79. The stock has a 50 day moving average price of $132.79 and a 200-day moving average price of $129.43. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.